A patient with multiple sclerosis is to begin treatment with interferon beta. The patient comes to the clinic to have pretreatment laboratory tests. Which statement by the patient indicates a need for further teaching about these tests?
a. After the first year of treatment, I will need once yearly blood work.
b. I will need to have lab tests done every 3 months for the first year.
c. If my liver function tests are abnormal, I will need to stop using this drug.
d. These lab tests will measure liver and bone marrow function.
Question 2
A patient administers interferon beta-1a SQ (Rebif) 22 mcg/0.5 mL three times each week.
The patient calls the nurse to report unrelieved itching and erythema at the injection site, despite the use of topical hydrocortisone for several weeks. What will the nurse tell this patient to do?
a. Apply ice to the injection site before and after the injection.
b. Ask the provider to reduce the dose of interferon beta to 8.8 mcg/0.2 mL.
c. Discuss using a prescription-strength hydrocortisone product with the provider.
d. Take oral diphenhydramine (Benadryl).
Molecular complementarity permits tight protein bonding via multiple noncovalent
Areas of sclerosis (see arrows) in the white matter of a patient with MS.
Pneumonia patient’s chest x-ray. Note the irregular areas of density.
Muscle weakness caused by myasthenia gravis is evident in the eyes of this patient.
Patient Physical Status Classification